Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT07917637

Ashwagandha Added to Risperidone for Quality of Life and Inflammation in Schizophrenia

Conditions: Schizophrenia

Sex: Male
Ages: 20 Years – 45 Years
Healthy volunteers: No
Phase: NA
Enrollment: 60
Sponsor: Athitah Pratiwi

Location: Rumah Sakit Khusus Daerah (RSKD) Dadi Provinsi Sulawesi Selatan Makassar South Sulawesi

Summary

Schizophrenia is a chronic mental health disorder that affects thinking, emotions, behavior, and quality of life. Although antipsychotic medications such as risperidone are commonly used to manage schizophrenia, some patients continue to experience psychiatric symptoms and reduced quality of life. Inflammation may also contribute to the development and severity of schizophrenia. Ashwagandha (Withania somnifera) is a medicinal plant with potential anti-inflammatory and neuroprotective properties. This study evaluated whether adding ashwagandha to standard risperidone treatment could improve quality of life, reduce psychiatric symptoms, and lower blood levels of tumor necrosis factor-alpha (TNF-alpha), a marker of inflammation, in patients with schizophrenia. This randomized, double-blind, placebo-controlled study included 60 male patients with schizophrenia aged 20 to 45 years. Participants were randomly assigned to receive either ashwagandha plus risperidone or placebo plus risperidone for eight weeks. Quality of life, psychiatric symptoms, and blood levels of TNF-alpha were assessed at the beginning of the study and after eight weeks of treatment. The study aimed to provide additional evidence regarding the potential benefits of ashwagandha as an adjunctive treatment for schizophrenia.

Eligibility Criteria

Inclusion Criteria: * Male patients aged 20-45 years. * Diagnosed with schizophrenia according to the International Classification of Diseases, 10th Revision (ICD-10), and the Indonesian Classification and Diagnostic Guidelines for Mental Disorders III (PPDGJ-III). * Duration of schizophrenia of five years or less since disease onset. * Having passed the acute agitation phase, defined by a Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) score below 15. * Receiving risperidone at a dose of 4 mg/day. * Able to read and write. * Willing to participate and able to provide written informed consent. Exclusion Criteria: * Presence of organic medical comorbidities. * Intellectual disability. * History of substance use within the preceding six months, except caffeine or nicotine. * Concurrent use of anti-inflammatory medications, antibiotics, or antioxidant supplements. * Changes in antipsychotic treatment during the screening period.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07917637). StuddyBuddy aggregates publicly available trial information.